Intelligence · Clinical Pipeline
Iovance Biotherapeutics Pipeline
All ClinicalTrials.gov programs at Iovance Biotherapeutics — phase, modality, and trial IDs.
- Programs
- 2
Quick answer
Iovance Biotherapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Lifileucel plus Pembrolizumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph
Iovance Biotherapeutics B.V.
Melanoma
1 trial
Frequently asked questions
How many pipeline programs does Iovance Biotherapeutics have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs